Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.

Although the onset time difference between females and males did not reach statistical significance (females vs. males: 15 vs. 5 days; P = 0.136), a discernible trend indicated longer onset times for females.

also in 111,027 other papers